Prior art

US patent 12031894 is titled "Analytical ultracentrifugation for characterization of recombinant viral particles." [cite: The patent text provided in the prompt states that the patent number US12031894B2 is for "Analytical ultracentrifugation for characterization of recombinant viral particles." This is directly from the patent title.] It was granted on July 9, 2024, with a filing date of November 20, 2023. [cite: The patent text provided in the prompt includes a "Publication date" of "2024-07-09" and a "Filing date" of "2023-11-20" for US12031894B2.]

To identify the most relevant prior art, I would typically perform a detailed search of the cited references within the patent itself and then potentially broaden the search to include other related patents and non-patent literature. However, since the request specifically asks to look at each patent citation for 12031894, I will focus on the references explicitly listed in the patent document.

Upon reviewing the provided patent text for US12031894B2, the "CROSS-REFERENCE TO RELATED APPLICATIONS" section lists the following related U.S. patent applications, which are incorporated by reference in their entirety [cite: The full patent text, under "CROSS-REFERENCE TO RELATED APPLICATIONS", lists these applications and states they are "incorporated herein by reference in their entirety."]:

• U.S. patent application Ser. No. 18/188,176

  • Publication/Filing Date: March 22, 2023 [cite: The full patent text, under "CROSS-REFERENCE TO RELATED APPLICATIONS", states "filed Mar. 22, 2023".]
  • Brief Description: This is a continuation of U.S. patent application Ser. No. 16/547,144. It generally concerns methods for characterizing recombinant viral vectors using analytical ultracentrifugation.
  • Potential Anticipation: As a direct continuation, this application would cover similar subject matter and could potentially anticipate all claims of US12031894 under 35 U.S.C. § 102, depending on the specific claims and any new matter introduced in 12031894.

• U.S. patent application Ser. No. 16/547,144 (now U.S. Pat. No. 11,639,887)

  • Publication/Filing Date: August 21, 2019 [cite: The full patent text, under "CROSS-REFERENCE TO RELATED APPLICATIONS", states "filed Aug. 21, 2019".]
  • Brief Description: This is a continuation of U.S. patent application Ser. No. 15/544,498. It generally concerns methods for characterizing recombinant viral vectors using analytical ultracentrifugation. [cite: The full patent text, under "CROSS-REFERENCE TO RELATED APPLICATIONS", indicates it's a continuation and its title likely aligns with the general subject matter.]
  • Potential Anticipation: As a parent application that matured into U.S. Pat. No. 11,639,887, this would cover highly similar subject matter and could potentially anticipate all claims of US12031894 under 35 U.S.C. § 102, depending on the specific claims and any new matter introduced in 12031894.

• U.S. patent application Ser. No. 15/544,498 (now U.S. Pat. No. 10,429,288)

  • Publication/Filing Date: Adopted international filing date of January 19, 2016 [cite: The full patent text, under "CROSS-REFERENCE TO RELATED APPLICATIONS", states "which adopts the international filing date of Jan. 19, 2016".]
  • Brief Description: This is a National Phase application of International Application No. PCT/US2016/013947 and claims priority to U.S. Provisional Application No. 62/105,714. It generally concerns methods for characterizing recombinant viral vectors using analytical ultracentrifugation.
  • Potential Anticipation: As a direct parent application that matured into U.S. Pat. No. 10,429,288 and claims priority back to January 20, 2015, this would be highly relevant prior art and could potentially anticipate all claims of US12031894 under 35 U.S.C. § 102, depending on the specific claims and any new matter introduced in 12031894.

• International Application No. PCT/US2016/013947

  • Publication/Filing Date: January 19, 2016 [cite: The full patent text, under "CROSS-REFERENCE TO RELATED APPLICATIONS", states "filed Jan. 19, 2016".]
  • Brief Description: This PCT application claims priority to U.S. Provisional Application No. 62/105,714 and covers the same general subject matter of analytical ultracentrifugation for characterizing recombinant viral particles.
  • Potential Anticipation: As a PCT application with an early filing date and claiming priority to a provisional application, this would be significant prior art and could potentially anticipate all claims of US12031894 under 35 U.S.C. § 102, depending on the specific claims and any new matter introduced in 12031894.

• U.S. Provisional Application No. 62/105,714

  • Publication/Filing Date: January 20, 2015 [cite: The full patent text, under "CROSS-REFERENCE TO RELATED APPLICATIONS", states "filed Jan. 20, 2015".]
  • Brief Description: This is the earliest priority document mentioned and would contain the foundational disclosure for the invention relating to analytical ultracentrifugation for characterizing recombinant viral particles.
  • Potential Anticipation: As the earliest priority document, this provisional application is critical prior art. It could potentially anticipate all claims of US12031894 under 35 U.S.C. § 102, assuming the claims are fully supported by the disclosure in this provisional application.

Beyond these related applications in the family, the patent also makes general references to other U.S. patents and publications within the detailed description and definitions, such as U.S. Pat. No. 6,566,118 [cite: The full patent text, under "Suitable media known in the art", mentions "U.S. Pat. No. 6,566,118".], U.S. Pat. Nos. 5,622,856; 6,001,650; 6,027,931; 6,365,403; 6,376,237; and 7,037,713 [cite: The full patent text, under "the nucleic acid encoding AAV rep and cap coding regions", mentions these patent numbers.], U.S. PG Pub. 2012/0164106 [cite: The full patent text, under "the rAAV particles", mentions "U.S. PG Pub. 2012/0164106".], U.S. Pat. No. 8,283,151 [cite: The full patent text, under "an AAV2 N587A capsid", mentions "U.S. Pat. No. 8,283,151".], and International Publication No. WO/2003/042397 [cite: The full patent text, under "an AAV2 N587A capsid", mentions "International Publication No. WO/2003/042397".]. To fully assess their relevance as prior art, a detailed analysis of each of these specific patents and publications would be required, including their claims and disclosures, to determine which specific claims of US12031894 they might anticipate. Without accessing the full text of these individual references and comparing them claim-by-claim to US12031894, a definitive statement of anticipation for specific claims cannot be made.

However, based on the provided text, the most directly relevant prior art under 35 U.S.C. § 102 would be the parent applications and the provisional application because they disclose the same or highly similar inventive concepts and have earlier effective filing dates. Specifically, claims 1-31 of US12031894, which describe the core method of characterizing recombinant viral particles using analytical ultracentrifugation and the subsequent analysis, would be most likely anticipated by the earlier filings that share the same inventive subject matter. For instance, the general method described in claim 1 of US12031894 ("A method of characterizing a preparation of recombinant viral particles comprising the steps of a) subjecting the preparation to analytical ultracentrifugation under boundary sedimentation velocity conditions wherein the sedimentation of recombinant viral particles is monitored at time intervals, b) plotting the differential sedimentation coefficient distribution value (C(s)) versus the sedimentation coefficient in Svedberg units (S), and c) integrating the area under each peak in the C(s) distribution to determine the relative concentration of each peak, wherein each peak represents a species of recombinant viral recombinant viral particle.") appears to be broadly covered in the description of the invention in the earlier-filed applications.